Cambridge, UK-based firm becomes Piramal Discovery Solutions
Piramal Pharma Solutions, a contract pharmaceutical services group, has re-branded its discovery chemistry and ADME services acquisition O2h to Piramal Discovery Solutions to reflect its expansion into the contract discovery and development services sector.
Piramal Pharma Solutions now offers integrated drug discovery solutions from discovery chemistry to clinical trials. It has nine specialist sites employing 2,500 people in India, the UK and Canada.
Piramal bought O2h’s discovery services business in February this year. Its capabilities include integrated teams of FTE-based medicinal chemistry, synthetic chemistry and in-vitro ADMET, with particular emphasis on rapid interactive communications and delivery speed.
The firm’s biology capability is currently being expanded.
‘The re-branding to Piramal Discovery Solutions reflects the aim of the group to be a fully integrated service provider to those that discover and develop new small molecule drugs for the treatment of disease,’ said Sunil Shah, chief executive of Piramal Discovery Solutions.
He added that the firm aims to provide robust technology transfer protocols between Piramal sites worldwide.
O2h was founded at Cambridge, UK in 2003. The team works from a project management office in Cambridge, and a research centre in Ahmedabad, India. Current clients include pharmaceutical and biotechnology companies in the US, Europe and Japan.
Piramal Discovery Solutions fits alongside Pharma Solutions’ three primary business units of Formulation Services, API Services and API Generics.